NLS COVID-19

New research shows that Pfizer’s and Moderna’s COVID-19 vaccines might offer protection for a longer time than previously thought. Protection could potentially last for years shows the new study by Turner et al., “SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses”, published in Nature. Germinal centers in the lymph nodes The study focused on […]

The first participants in a Phase II/III trial for AstraZeneca’s new COVID-19 variant vaccine AZD2816 have been vaccinated to assess its safety and immunogenicity in both previously vaccinated and unvaccinated adults. The trial will recruit approximately 2,250 participants across UK, South Africa, Brazil and Poland. The same adenoviral vector platform as Vaxzevria AZD2816 will be […]

Researchers at Karolinska Institutet in Sweden have developed a new method, named COVseq, that can be used for surveillance of the viral genome on a massive scale at a low cost. For global surveillance of the SARS-CoV-2 genome, it is crucial to sequence and analyze many samples in a cost-effective way. Therefore, researchers in the […]

SciLifeLab has been commissioned by the Swedish government to support important societal functions in coordinated improvement of laboratory preparedness during possible coming pandemics. The aim is to strengthen Sweden’s preparedness in the event of a new pandemic or other crisis that requires national laboratory coordination, states SciLifeLab in a press release. Investment in laboratory support […]

CureVac has announced results of the second interim analysis of its international Phase 2b/3 study in approximatively 40,000 subjects (the HERALD study) of CureVac’s first-generation COVID-19 vaccine candidate, CVnCoV. In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy […]

The company has announced results from a trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The trial did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19 with AZD7442 compared to placebo, writes the […]